Paul Shami, MD
Medical Oncology · Salt Lake City, UTNPI 1992895510
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,688 of the $28,422 with a category attached, or 62.2%. It is spread thinly across 10 manufacturers, the largest accounting for just 20.4%. Reporting peaked in 2019 at $19,360 and has fallen 85.0% since, to $2,910 in 2022.
Across 43 payments — averaging $660.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$6K
- AbbVie$5K
- Agios Pharmaceuticals, Inc.$4K
- Pfizer$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Bristol Myers Squibb$2K
- plus $4K from 4 others
Across 65 payments — averaging $23,169 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$766K
- Sumitomo Pharma America, Inc.$403K
- Aptevo Therapeutics Inc$217K
- Syndax Pharmaceuticals, Inc.$91K
- E.r. Squibb & Sons, L.L.C.$27K
- Novartis$2K
What the payments were for
- Consulting fees$17,68862%
- Speaking & faculty fees$6,78024%
- Travel & lodging$3,40712%
- Food & beverage$5472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 10 | $5,799 |
| AbbVie | 15 | $5,328 |
| Agios Pharmaceuticals, Inc. | 10 | $4,200 |
| Pfizer | 2 | $3,980 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,300 |
| Bristol Myers Squibb | 1 | $2,063 |
| Daiichi Sankyo Inc. | 1 | $1,935 |
| E.r. Squibb & Sons, L.L.C. | 1 | $975 |
| Gilead | 1 | $790 |
| Aptevo Therapeutics Inc | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,422 in reported general payments places this provider in the 75th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 21 | $815,778 |
| SprycelDasatinib | 25 | $411,326 |
| ScemblixAsciminib Hydrochloride | 19 | $397,246 |
| OnuregAzacitidine | 16 | $310,642 |
| VenclextaVenetoclax | 15 | $38,204 |
| Posaconazole | 17 | $13,655 |
| Acyclovir | 82 | $1,162 |
| Cyclosporine ModifiedCyclosporine, Modified | 16 | $933 |
| Fluconazole | 11 | $653 |
| Potassium Chloride | 39 | $296 |
| Levofloxacin | 20 | $246 |
| Prochlorperazine Maleate | 16 | $193 |
| Ondansetron Hcl | 17 | $127 |
| Allopurinol | 15 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel, Onureg | $975 | $721,96841 claims |
| AbbVieVenclexta | $5,328 | $38,20415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 medical oncology providers in Utah.
Other medical oncology in Salt Lake City
- Bradley HunterSalt Lake City$263K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Nitin ChandramouliSalt Lake City$19K
- Kenneth GrossmannSalt Lake City$15K
- Manish KohliSalt Lake City$13K
- Peter HaleSalt Lake City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.